The Number of Coronavirus Disease 2019 Vaccine Doses and Severe Clinical Outcomes in Older Patients Infected With a Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
The Number of Coronavirus Disease 2019 Vaccine Doses and Severe Clinical Outcomes in Older Patients Infected With a Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
复制标题
感染严重急性呼吸系统综合症冠状病毒 2 Omicron 变种的老年患者的 2019 年冠状病毒病疫苗剂量和严重临床结果
DOI：
10.1093/infdis/jiac395
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Yasuko Mori
中科院分区：
文献类型：
--
作者：
Koichi Furukawa;Yukiya Kurahashi;Hanako Ishimaru;Mitsuhiro Nishimura;Jun Arii;Shigeru Sano;Yoshiki Tohma;Hiroyuki Ohkita;Sachiko Nakamura;Sachiyo Iwata;Yasuko Mori
Mwimanzi等人最近报告说，2019年冠状病毒病（COVID-19）疫苗的第三剂增强了老年人的Omicron特异性中和作用，他们指出，慢性健康状况的数量是体液反应较弱的最强因素，表明第三剂疫苗的免疫益处[1]。患有合并症的老年人和个体患严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染引起的致命COVID-19疾病的风险增加[2，3]。SARS-CoV-2 Omicron变异体的传播比以前的变异体更大，已经出现了几个突变，特别是在刺突蛋白中;一些突变对于免疫逃逸是重要的，因此Omicron变体迅速传播并成为一个重要的世界性问题[4]。因此，重要的是确定第三剂疫苗是否会影响感染Omicron变异体的COVID-19患者的疾病严重程度。我们调查了23名COVID-19变得严重并在感染Omicron BA后入住兵库县加古川医疗中心（日本兵库县加古川市）重症监护室的患者的临床特征。1或BA。2022年1月至3月3个月期间的2种变体（表1）。
To the Editor—Mwimanzi et al recently reported that the third dose of a coronavirus disease 2019 (COVID-19) vaccine boosted Omicron-specific neutralization in older individuals, and they noted that the number of chronic health conditions was the strongest factor of weaker humoral responses, indicating the immune benefits of a third vaccine dose [1]. Older adults and individuals with comorbidities are at increased risk of lethal COVID-19 disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [2, 3]. SARS-CoV-2 Omicron variants, the transmission of which is greater than that of previous variants, have appeared with several mutations, especially in the spike protein; some of the mutations are important for immune escape, and Omicron variants have thus spread rapidly and become an important, worldwide problem [4].It is, therefore, important to determine whether a third vaccine dose affects disease severity among COVID-19 patients infected with an Omicron variant. We investigated the clinical features of 23 patients whose COVID-19 became severe and who were admitted to the intensive care unit at Hyogo Prefectural Kakogawa Medical Center (Kakogawa, Hyogo, Japan) after they were infected with the Omicron BA. 1 or BA. 2 variant during the 3-month period of January–March 2022 (Table 1).
老年人对两剂 COVID-19 mRNA 疫苗的持久体液反应较弱，但对第三剂疫苗的初步反应强烈
DOI：
10.1101/2022.01.06.22268745
发表时间：
2022
期刊：
medRxiv
影响因子：
--
作者：
F. Mwimanzi;H. Lapointe;P. Cheung;Yurou Sang;F. Yaseen;G. Umviligihozo;R. Kalikawe;Sneha Datwani;F. H. Omondi;L. Burns;L. Young;V. Leung;O. Agafitei;S. Ennis;W. Dong;Simran Basra;L. Y. Lim;Kurtis Ng;R. Pantophlet;C. Brumme;J. Montaner;N. Prystajecky;C. Lowe;Mari L. DeMarco;D. Holmes;J. Simons;M. Niikura;M. Romney;Z. Brumme;M. Brockman
通讯作者：
M. Brockman
人呼吸道组织中SARS-CoV-2感染相关体内因子的表达及其个体差异
DOI：
--
发表时间：
2022
期刊：
影响因子：
--
作者：
Masaru USUI;平井杏梨，杉尾翔太，池中良徳，Collins Nimako，中山翔太，星信彦，和氣弘明，石塚真由美;Fumiyuki Nakajima;作野裕司，比嘉紘士，小林拓;堤 亜里沙，小林 叶奈，河村 伊久雄，三浦 伸彦，森 葉子，礒部 隆史，大河原 晋，埴岡 伸光，神野 透人，香川（田中） 聡子
通讯作者：
堤 亜里沙，小林 叶奈，河村 伊久雄，三浦 伸彦，森 葉子，礒部 隆史，大河原 晋，埴岡 伸光，神野 透人，香川（田中） 聡子